You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Effects of the AT₁ Receptor Antagonist L-158,809 on Microglia and Neurogenesis after Fractionated Whole-Brain Irradiation
Kelly R. Conner, Valerie S. Payne, M. Elizabeth Forbes, Mike E. Robbins and David R. Riddle
Vol. 173, No. 1 (Jan., 2010), pp. 49-61
Published by: Radiation Research Society
Stable URL: http://www.jstor.org/stable/40539814
Page Count: 13
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Cognitive dysfunction develops in approximately 50% of patients who receive fractionated whole-brain irradiation and survive 6 months or more. The mechanisms underlying these deficits are unknown. A recent study demonstrated that treatment with the angiotensin II type 1 receptor antagonist (AT₁ RA) L-158,809 before, during and after fractionated wholebrain irradiation prevents or ameliorates radiation-induced cognitive deficits in adult rats. Given that (1) AT, RAs may function as anti-inflammatory drugs, (2) inflammation is thought to contribute to radiation injury, and (3) radiation-induced inflammation alters progenitor cell populations, we tested whether the cognitive benefits of L-158,809 treatment were associated with amelioration of the sustained neuroinflammation and changes in neurogenesis that are induced by fractionated whole-brain irradiation. In rats examined 28 and 54 weeks after irradiation, L-158,809 treatment did not alter the effects of radiation on the number and activation of microglia in the perirhinal cortex and hippocampus, nor did it prevent the radiation-induced decrease in proliferating cells and immature neurons in the hippocampus. These findings suggest that L-158,809 does not prevent or ameliorate radiation-induced cognitive deficits by modulation of chronic inflammatory mechanisms, but rather may reduce radiation-induced changes that occur earlier in the postirradiation period and that lead to Cognitive dysfunction.
Radiation Research © 2010 Radiation Research Society